News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 7870
- Sources here
- 17
- Companies here
- 33
Search results
Stored financial headlines
Active search
7870 matching headlines
Ticker or company: APEMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …
TRAX
main company
Sharemaestro market context
Stored weekly price path
17 weeks +142.5% · Next-week setup positive 60.9%
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026
Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …
IOVA
main company
Sharemaestro market context
Trend signal active
52 weeks +159.5% · Next-week setup negative 42.7%
BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating
BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.
AARD
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.1%
Corcept therapeutics chief development officer sells $1.8m in stock
William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …
CORT
main company
Sharemaestro market context
Trend signal active
52 weeks +62.8% · Next-week setup positive 56.8%
BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20
BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.
MPLT
main company
Sharemaestro market context
Price below Trend Line
42 weeks -30.6%
Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock
Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …
AVTX
main company
Sharemaestro market context
Trend signal active
52 weeks +98.3% · Next-week setup negative 44.7%
PTC Therapeutics Is Maintained at Overweight by Barclays
Barclays has reiterated its 'Overweight' rating on PTC Therapeutics (PTCT). The analyst firm maintained a price target of $70.00 for the company's stock. This indicates a positive outlook from Barclays regarding PTC Therapeutics' future performance.
PTCT
main company
Sharemaestro market context
Trend signal active
52 weeks +41.8%
Aperam (ENXTAM:APAM) Stock May Be 40% Undervalued On Cash Flow
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Aperam stock has logged a strong run over the past few years, yet current checks suggest the market price may still sit below …
Sharemaestro market context Trend signal active 52 weeks +86.0% · Next-week setup positive 59.4%Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants
Outlook Therapeutics' CFO, Lawrence A. Kenyon, purchased 101,010 shares of common stock and 101,010 accompanying warrants in an underwritten public offering on August 14, 2026. The combined offering price was $0.99 per share and warrant, with the warrants immediately exercisable at $1.10 and expiring …
OTLK
main company
Sharemaestro market context
Trend signal active
52 weeks -71.8%
Edgewise Therapeutics CEO Kevin Koch sells $785,042 in stock
Edgewise Therapeutics CEO Kevin Koch sold $785,042 worth of company stock on August 12, 2026, primarily to cover tax obligations related to Restricted Stock Unit vesting. Despite the sales, Mr. Koch also acquired new shares through vesting and was granted additional RSUs and stock …
EWTX
main company
Sharemaestro market context
Trend signal active
52 weeks +197.4%
Walleye Capital LLC Takes $1.59 Million Position in PTC Therapeutics, Inc. $PTCT
Walleye Capital LLC has acquired a new position in PTC Therapeutics, Inc., purchasing 19,522 shares valued at approximately $1.59 million during the second quarter. Several other institutional investors also increased their holdings in the biopharmaceutical company, which has an average analyst rating of "Moderate …
PTCT
main company
Sharemaestro market context
Trend signal active
52 weeks +41.8%
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST
Walleye Capital LLC has acquired a new stake of 282,568 shares in Aquestive Therapeutics, Inc. (NASDAQ:AQST), valued at approximately $1.18 million. Institutional investors collectively hold 32.45% of the company's stock, while insider ownership stands at 6.81%. Despite a wider-than-expected quarterly loss, analysts maintain a …
AQST
main company
Sharemaestro market context
Price above Trend Line
52 weeks +6.8%
8,393 Shares in Tapestry, Inc. $TPR Bought by Summit Global Investments
Summit Global Investments purchased 8,393 shares of Tapestry, Inc. (TPR) for approximately $1.23 million in the second quarter, making it one of many institutional investors holding 90.77% of the company's stock. Tapestry recently exceeded fourth-quarter earnings and revenue expectations, reporting an EPS of $1.32 …
TPR
main company
Sharemaestro market context
Trend signal active
52 weeks +31.1% · Next-week setup positive 57.2%
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell"
Zacks Research downgraded Mineralys Therapeutics (NASDAQ:MLYS) to a "Strong Sell" rating, despite a mixed analyst sentiment with an average "Hold" rating and a $49.33 price target. The downgrade follows a significant earnings miss, with the company reporting a quarterly loss of $2.85 per share …
MLYS
main company
Sharemaestro market context
Price below Trend Line
52 weeks +72.3%
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold
Zacks Research downgraded Monopar Therapeutics (NASDAQ:MNPR) from a "strong-buy" to a "hold" rating, despite the broader analyst consensus remaining a "moderate buy" with an average price target of $117.42. The company's shares opened at $113.04, trading near their 12-month high, and it recently reported …
MNPR
main company
Sharemaestro market context
Trend signal active
52 weeks +252.6%
Walleye Capital LLC Purchases Shares of 102,163 Rapport Therapeutics, Inc. $RAPP
Walleye Capital LLC has acquired a new position in Rapport Therapeutics, purchasing 102,163 shares valued at $4.26 million, representing 0.21% of the company. Despite the stock opening near its 52-week high, Rapport Therapeutics reported a quarterly loss of $1.19 per share, missing estimates. Analysts …
RAPP
main company
Sharemaestro market context
Trend signal active
52 weeks +221.1% · Next-week setup positive 59.6%
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC
Walleye Capital LLC has acquired 128,006 shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the second quarter, a position valued at approximately $3.82 million. Despite this acquisition and a consensus "Buy" rating from analysts with an average price target of $66, the company reported a …
MAZE
main company
Sharemaestro market context
Price below Trend Line
52 weeks +101.5%
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO
Walleye Capital LLC has invested $6.80 million in Allogene Therapeutics, acquiring 3.27 million shares, representing approximately 0.95% of the company. Other institutional investors have also adjusted their stakes, with a significant 83.63% of the stock owned by institutional investors and hedge funds. Allogene Therapeutics …
ALLO
main company
Sharemaestro market context
Price below Trend Line
52 weeks +72.3%
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI
Walleye Capital LLC has acquired a new stake of 241,987 shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) during the second quarter, valued at approximately $4.5 million. This investment contributes to the 95.76% institutional ownership of the company. Trevi Therapeutics maintains a "Buy" consensus rating from …
TRVI
main company
Sharemaestro market context
Trend signal active
52 weeks +144.5%